Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.
Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.
With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.
Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.
Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.
For the latest updates and further information, visit www.integralife.com.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported Q3 2022 revenues of $385 million, a decrease of 0.4% year-over-year, with a 3.5% increase on an organic basis. GAAP earnings per diluted share rose to $0.60, compared to $0.51 last year. The company raised its EPS outlook to $3.29-$3.33 and reaffirmed revenue guidance between $1,551-$1,563 million, indicating organic growth of 3.7%-4.5%. The TWC business was sold for $28.8 million, and cash flow from operations reached $68 million. Full-year guidance reflects adjustments due to foreign currency impacts.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) plans to release its third quarter 2022 financial results on October 26, 2022, before market opening. This will be followed by a conference call hosted by the management team at 8:30 a.m. ET. Investors can access the call by dialing 866-571-0905 with passcode 1121226# or through a live webcast on the company’s website. A replay will be available until November 7, 2022.
Integra LifeSciences (NASDAQ: IART) announced the appointment of Harvinder Singh as executive vice president and president of its international business. Singh brings over 20 years of experience from Abbott Laboratories, where he held various senior roles, including vice president of global commercial operations in the vascular sector. His expertise is expected to support Integra's growth strategy in international markets. Singh holds degrees in chemistry and biology from Punjab University and an MBA from the University of Indore, along with completing the Harvard Business School’s Advanced Management Program.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its participation in two upcoming investor conferences. CEO Jan De Witte will present at the Wells Fargo 2022 Healthcare Conference in Boston on September 7, 2022, at 8:35 am ET. CFO Carrie Anderson will speak at the Morgan Stanley Annual Global Healthcare Conference in New York on September 12, 2022, at 11:05 am ET. Interested parties can find webcast information on the Company’s website.
Integra LifeSciences (NASDAQ:IART) announced the passing of Dr. Richard Caruso, founder and former chairman and CEO, on August 14, 2022. Dr. Caruso's vision revolutionized the field of regenerative medicine, leading to groundbreaking products like the Integra Dermal Regeneration Template approved by the FDA in 1996. His leadership from 1992 to 2011 established Integra as a global leader in regenerative tissue technologies. The company continues to improve patient care through its diverse portfolio, enhancing surgical outcomes worldwide. The impact of Dr. Caruso's work will be felt for generations.
Integra LifeSciences Holdings Corporation (IART) reported Q2 2022 revenues of $398 million, reflecting a 2.0% increase year-over-year. Adjusted earnings per diluted share reached $0.82, up from $0.79 in the previous year. The company has updated its full-year 2022 guidance, expecting revenues between $1,557 million and $1,575 million, amid divestiture plans for its non-core traditional wound care business. Strong performance in the Codman Specialty Surgical and Tissue Technologies segments was noted, along with cash flow from operations of $66 million.
Integra LifeSciences Holdings Corporation (Nasdaq: IART) has appointed Renee Lo as an independent director, effective July 18, 2022. Lo brings significant experience in digital transformation from her role at Microsoft, where she leads data and AI business in Asia. She has a background at Amazon Web Services and extensive experience in the technology sector, holding leadership roles in product development and corporate strategy. This addition aims to enhance the board's capability in delivering shareholder value.
Integra LifeSciences (NASDAQ: IART) will release its second quarter 2022 financial results on July 27, 2022, before the market opens. Following the release, management will hold a conference call at 8:30 a.m. ET, accessible by calling 800-289-0720 with the passcode 2688312. A webcast of the call will also be available on their website, with a replay accessible until August 7, 2022. Integra specializes in regenerative tissue technologies and offers a broad portfolio of recognized brands aimed at enhancing patient care.
On May 11, 2022, Hilco Redevelopment Partners announced that Integra LifeSciences (IART) will occupy 100,000 square feet of newly redeveloped space at 400 Wood Road in Braintree, MA. This facility will manufacture surgical reconstruction devices, contributing significantly to local job creation with at least 150 new positions. The Braintree Town Council approved a tax increment financing (TIF) agreement to support this development. Integra plans to achieve full occupancy by late 2025, aiming to positively impact the local economy.
FAQ
What is the current stock price of Integra LifeSciences Holdings (IART)?
What is the market cap of Integra LifeSciences Holdings (IART)?
What does Integra LifeSciences Holdings Corp. specialize in?
Where is Integra LifeSciences headquartered?
What are the primary segments of Integra LifeSciences?
What recent acquisition was announced by Integra LifeSciences?
What are some of the key products offered by Integra LifeSciences?
How did Integra perform financially in the second quarter of 2023?
What is the purpose of Integra’s CereLink ICP Monitoring System?
How many employees does Integra LifeSciences have?
Which markets does Integra LifeSciences serve?
What is Integra’s strategy for growth in 2024?
